Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16071242 | 0.91 | ROCK1 (0.58) | ROCK1SMN1; SMN2HTTLMNATP53 | |
| SCHEMBL6762394 | 0.83 | ROCK1 (0.51) | ROCK1SMN1; SMN2HTTLMNATP53 | |
| SCHEMBL9379055 | 0.77 | ROCK1 (0.55) | ROCK1SMN1; SMN2HTTLMNATP53 | |
| SCHEMBL9379977 | 0.76 | ROCK1 (0.61) | ROCK1SMN1; SMN2HTTLMNATP53 | |
| SCHEMBL28609745 | 0.75 | ROCK1 (0.60) | ROCK1SMN1; SMN2HTTLMNATP53 | |
| SCHEMBL30362762 | 0.75 | ROCK1 (0.53) | ROCK1SMN1; SMN2LMNATP53MAPK1 | |
| SCHEMBL28667775 | 0.75 | ROCK1 (0.53) | ROCK1SMN1; SMN2LMNATP53MAPK1 | |
| SCHEMBL31218789 | 0.74 | ROCK1 (0.58) | ROCK1SMN1; SMN2HTTLMNATP53 | |
| SCHEMBL6071629 | 0.73 | ROCK1 (0.62) | ROCK1SMN1; SMN2LMNATP53MAPK1 | |
| SCHEMBL29721478 | 0.73 | ROCK1 (0.62) | ROCK1SMN1; SMN2LMNATP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Education, on behalf of the Univ of Nevada, Reno (US) | 2019-08-08 | — | — | US | disclosed |
| US-10206903-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-02-19 | — | — | US | disclosed |
| US-9980943-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEMS OF HIGHER EDUCATION ON BEHALF OF THE NEVADA, RENO (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980943-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEMS OF HIGHER EDUCATION ON BEHALF OF THE NEVADA, RENO (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170340606-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340606-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2017-11-30 | — | — | US | disclosed |
| US-9707210-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707210-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160030390-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Ed ucation on behalf of the University of Nevada Ren (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160030390-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Ed ucation on behalf of the University of Nevada Ren (US) | 2016-02-04 | — | — | US | disclosed |
| WO-2014144606-A2 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-0422178-B1 | PYRIMIDINE DERIVATIVES | ZENECA LTD (GB) | 1994-10-05 | — | — | EP | disclosed |
| US-5223505-A | PYRIMIDINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-29 | — | — | US | disclosed |
| EP-0422178-A1 | PYRIMIDINE DERIVATIVES. | ICI PLC (GB) | 1991-04-17 | — | — | EP | disclosed |
| WO-1990012790-A1 | PYRIMIDINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | ROCK1 2510/4885SMN1; SMN2 22/4885HTT 4298/4885 |
| US-10206903-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | ROCK1 2510/4885SMN1; SMN2 22/4885HTT 4298/4885 |
| US-20170340606-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | ROCK1 2510/4885SMN1; SMN2 22/4885HTT 4298/4885 |
| US-20160030390-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | ROCK1 2510/4885SMN1; SMN2 22/4885HTT 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.